Document is current
Any future updates will be listed below
-
Authors
Ng, Mei Ying
Nix, Meredith N.
Du, Guangyan
Davidek, Ivan
Burger, Nils
Shin, Sanghee https://orcid.org/0000-0002-8786-6995
Toenjes, Sean https://orcid.org/0000-0001-8782-3023
Takeda, Haruna
Cheah Xin Yan, Megan https://orcid.org/0009-0006-5441-9642
Zhang, Bingsen https://orcid.org/0000-0001-8119-1715
Xiao, Haopeng https://orcid.org/0000-0002-4166-647X
Wei, Shelley M.
Seo, Hyuk-Soo https://orcid.org/0000-0003-0646-2102
Dhe-Paganon, Sirano https://orcid.org/0000-0003-0824-5929
Wales, Thomas E. https://orcid.org/0000-0001-6133-5689
Engen, John R. https://orcid.org/0000-0002-6918-9476
Mills, Evanna L. https://orcid.org/0000-0003-0447-8995
Che, Jianwei https://orcid.org/0000-0003-4956-4811
Zhang, Tinghu
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Chouchani, Edward T. https://orcid.org/0000-0002-9776-8790
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 18 December 2024
Accepted: 2 February 2026
First Online: 12 March 2026
Competing interests
: E.T.C. is cofounder of Matchpoint Therapeutics and Aevum Therapeutics. J.C. is a cofounder of Matchpoint Therapeutics, scientific cofounder of M3 Bioinformatics and Technology and consultant and equity holder for Soltego and Allorion. N.S.G. is a founder, science advisory board member and equity holder for Syros, C4, Allorion, Lighthorse, Inception, Matchpoint, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The N.S.G. lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. M.Y.N., M.N.N., G.D., E.T.C., J.C., T.Z. and N.S.G. are inventors on a patent WO/2025/109475 for the SHP1 compounds described in this work. The other authors declare no competing interests.
